A new feature is debuting on the Contract Pharma website: “The Friday Brief,” hosted by Content Marketing Editor Patrick Lavery. This video will drop every Friday morning, and serve as a week-in-review of some of our best coverage. Let’s jump right in.

We lead off with a few acquisitions this week. Gilead Sciences is acquiring Tubulis, a German company that develops ADCs. Neurocrine Biosciences is buying out Soleno Therapeutics at a stock price worth nearly $3 billion. And Vion Biosciences has acquired Cellular Technology Limited, which provides immune monitoring services and software.

In pharma collaborations, Lilly and AC Immune are amending their 2018 R&D agreement for Tau aggregation inhibitor small molecules to potentially treat Alzheimer’s and other neurodegenerative diseases. Touchlight and SVF Vaccines have partnered to advance a hepatitis B/D vaccine into clinical development; this leverages a proprietary platform based on what’s called doggybone DNA.

Cartherics and Catalent are expanding their partnership to manufacture and commercialize iPSC-derived CAR-NK cell therapies. Akari Therapeutics and Wuxi XDC are accelerating development of a novel PH1 payload, initially targeted for urothelial cancer. Halozyme and Vertex are collaborating to license up to three drug targets. And in the Asia-Pacific region, Daiichi Sankyo and ATLATL have a new R&D agreement.

A few companies are making internal moves this week. Allucent is expanding its CRO focus across oncology, neuroscience, cell and gene therapy, and other areas. Scinai Immunotherapeutics has completed a corporate reorganization separating its CDMO and R&D operations. Meanwhile, Ofichem is bringing its CDMO and pharma brands under a single identity.

That should be plenty to entice you to read the rest of our coverage from a very busy week in the industry, which you can do anytime at contractpharma.com.